intracellulartherapies.com (ITCI) - Company Sales

Biopharmaceutical leader Intra-Cellular Therapies (ITCI) is generating a powerful cash flow driven by the success of Caplyta. The drug's unique safety profile allows the company to maintain premium pricing power, and the company's sales volume on GURU.Markets confirms this trend, where the parameter value reaches 0.68. Such growth is based on a sovereign development cycle, transforming the asset into a reliable defensive tool independent of macroeconomic conditions.

ITCI Intra-Cellular Therapies: Company Revenue in the range 07/04/2022 - 04/13/2025

Analytical breakdowns for Intra-Cellular (ITCI)

- current quotes and average value forecast:

Price Rate Chart Intra-Cellular Therapies|ITCI - Analyst Consensus Forecast

- market capitalization indicators:

Market Valuation Intra-Cellular Therapies Inc.|ITCI - Enterprise Value

- balance sheet equity data:

Net Asset Value per Share Intra-Cellular Therapies|ITCI - Company Book Value|Market Value to Book Value Ratio intracellulartherapies.com|ITCI - Aggregate Company Assets

- debt and solvency information:

Debt to Equity Intra-Cellular Therapies|ITCI - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital intracellulartherapies.com|ITCI - Company Debts|Debt to Book Capitalization Ratio Intra-Cellular Therapies Inc.|ITCI - Company Long-Term Debts|Company Short-Term Debts Intra-Cellular Therapies|Intermediate Coverage Ratio intracellulartherapies.com

- business earnings and investment ratios data:

ITCI - Net Income|Expected Net Income Intra-Cellular Therapies|ITCI - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Intra-Cellular Therapies|ITCI - PEG Multiple|Business Value to Operating Income Before Depreciation Intra-Cellular Therapies Inc.|ITCI - Operating profit EBITDA|Net earnings per one share for the last twelve months Intra-Cellular Therapies|ITCI - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months intracellulartherapies.com|ITCI - Earnings growth in current year|Earnings growth forecast for next year Intra-Cellular Therapies

- sales volume and revenue indicators:

ITCI - Company Revenue|Company Expected Revenue Intra-Cellular Therapies|ITCI - P/S Multiple|Market Cap to Expected Sales Ratio Intra-Cellular Therapies Inc.|ITCI - Sales Growth YoY (TTM)

Comprehensive company analysis:Intra-Cellular Therapies, Inc.

To separate fundamental stability from market noise, it is essential for investors to evaluate the aggregate cash flow from product sales, which measures the actual scale of the issuer's trading activity. By analyzing the sales revenue chart for Intra-Cellular Therapies (ITCI), one can confirm the effectiveness of the company's strategy to commercialize psychiatric drugs developed in close partnership with leading specialized clinics and medical experts.

Key competitors